NEW DELHI: Cognizant is advancing the appliance of generative AI expertise with the NVIDIA BioNeMo platform to resolve complicated challenges of drug discovery within the life sciences business. This is anticipated to enhance productiveness within the growth course of and enhance the velocity at which new, life-saving remedies might be introduced to market, says an organization assertion.
Traditional drug discovery methodologies are course of intensive and require the evaluation of huge repositories of scientific literature and scientific knowledge so as to reveal related insights. Moreover, conventional strategies are burdened with excessive prices and lengthy growth lifecycles with a excessive charge of failure. By leveraging gen AI applied sciences, scientific researchers can quickly sift by way of in depth datasets, extra precisely predict interactions between drug compounds and create new, viable drug growth pathways.
“More than any other technological breakthrough in recent decades, generative AI has the potential to revolutionize the way new drugs are researched, developed and brought to market, making the creation of lifesaving discoveries faster, smarter and more accessible to all,” mentioned Anna Elango, EVP, Cognizant’s Core Technologies & Insights. “By collaborating with NVIDIA, Cognizant can open the path to realizing this vision safely, responsibly and cost-effectively for our life sciences clients.”
“Generative AI will drive the next wave of enterprise productivity gains across industries, enabled by the NVIDIA AI Enterprise software platform,” mentioned Alvin DaCosta, VP, international consulting companion group, NVIDIA.
Traditional drug discovery methodologies are course of intensive and require the evaluation of huge repositories of scientific literature and scientific knowledge so as to reveal related insights. Moreover, conventional strategies are burdened with excessive prices and lengthy growth lifecycles with a excessive charge of failure. By leveraging gen AI applied sciences, scientific researchers can quickly sift by way of in depth datasets, extra precisely predict interactions between drug compounds and create new, viable drug growth pathways.
“More than any other technological breakthrough in recent decades, generative AI has the potential to revolutionize the way new drugs are researched, developed and brought to market, making the creation of lifesaving discoveries faster, smarter and more accessible to all,” mentioned Anna Elango, EVP, Cognizant’s Core Technologies & Insights. “By collaborating with NVIDIA, Cognizant can open the path to realizing this vision safely, responsibly and cost-effectively for our life sciences clients.”
“Generative AI will drive the next wave of enterprise productivity gains across industries, enabled by the NVIDIA AI Enterprise software platform,” mentioned Alvin DaCosta, VP, international consulting companion group, NVIDIA.
